Overview
Cefuroxime is a well-established, broad-spectrum second-generation cephalosporin antibiotic. It offers enhanced activity against many Gram-negative bacteria compared to first-generation cephalosporins, while retaining robust efficacy against Gram-positive organisms. This balanced spectrum makes it a highly versatile and frequently utilized antibiotic in both outpatient and hospital settings. It is indicated for a wide range of infections, including acute otitis media, pharyngitis, tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated skin and soft tissue infections, early Lyme disease, and uncomplicated urinary tract infections.

Mechanism of Action
Like all beta-lactam antibiotics, cefuroxime exerts its bactericidal action by inhibiting bacterial cell wall synthesis. It achieves this by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. This binding inactivates the enzymes responsible for cross-linking peptidoglycan strands, a critical step for maintaining cell wall strength and rigidity. The resulting weakened cell wall is unable to withstand internal osmotic pressure, leading to cell lysis and bacterial death. Notably, cefuroxime demonstrates significant stability against degradation by many beta-lactamases produced by resistant bacteria.

Dosage and Administration
Cefuroxime is available in both oral (cefuroxime axetil) and intravenous/intramuscular (cefuroxime sodium) formulations. For adults taking the oral form, the typical dosage is 250 mg to 500 mg twice daily for 7 to 10 days, depending on the infection’s severity. For early Lyme disease, a 20-day course of 500 mg twice daily is recommended. Pediatric oral dosing is usually weight-based (e.g., 20 to 30 mg/kg/day divided into two doses). The oral suspension and tablets are not bioequivalent. It is strongly recommended to take the oral formulations with food to significantly enhance absorption and bioavailability.

Side Effects and Risks
Cefuroxime is generally well-tolerated. The most frequently reported adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and abdominal pain. As with many broad-spectrum antibiotics, its use can alter the normal intestinal flora, potentially leading to overgrowth of Clostridioides difficile and subsequent antibiotic-associated colitis, which can be severe. Other less common side effects include transient elevations in liver enzymes, mild skin rashes, and rarely, more severe allergic reactions.

Contraindications
The primary contraindication is a known hypersensitivity to cefuroxime or other cephalosporin antibiotics. Due to the potential for cross-reactivity (estimated at 5-10%), it should be used with extreme caution, or avoided entirely, in patients who have experienced a severe, immediate hypersensitivity reaction (like anaphylaxis) to penicillins. Dose adjustments are required for patients with significant renal impairment, as the drug is primarily excreted by the kidneys.

Pregnancy and Lactation
Cefuroxime is generally considered safe for use during pregnancy. Animal reproduction studies have not shown evidence of fetal harm, and extensive clinical experience has not indicated an increased risk of birth defects. It is often used to treat infections in pregnant women when clearly indicated. Cefuroxime is excreted in human breast milk in small quantities. While it is generally considered compatible with breastfeeding, the infant should be observed for potential side effects such as diarrhea or fungal infections (thrush).